🧬 BDNF Extraction Viewer

Извлечено: 997 / 997 (100.0%) Средняя confidence: 0.13
← Назад к списку

Bridging exercise biology and immunometabolism: A novel irisin pathway toward next-generation metabolic and neurodegenerative therapies.

PMID: 42004824 · DOI: 10.1016/j.metop.2026.100466 · Metabolism open, 2026 · Maria Dalamaga
📄 Abstract

Recent work by Mu et al. identifying irisin as a modulator of adipose tissue IL-33 and regulatory T cells introduces a new paradigm in immunometabolic biology, shifting attention from thermogenesis alone toward immune-stromal crosstalk as a determinant of metabolic health. By inducing IL-33 production in adipose mesenchymal stromal cells, irisin preserves ST2+ regulatory T cells (Tregs) in visceral adipose tissue, thereby restraining inflammation, improving insulin sensitivity, and promoting metabolic homeostasis. This mechanism expands the concept of exercise-induced metabolic protection by highlighting adipose tissue immune niches as critical targets of myokine action. In parallel, emerging evidence from preclinical models indicates that irisin-driven IL-33 signaling in subcutaneous adipose tissue contributes to thermogenic activation through mechanisms distinct from Treg-mediated immune regulation, highlighting depot-specific effects of this pathway. Beyond adipose tissue, irisin has emerged as a pleiotropic mediator with reported roles in glucose homeostasis, cardiovascular protection, and neurobiology. Importantly, accumulating evidence indicates that irisin may also exert neuroprotective effects, including the induction of brain-derived neurotrophic factor (BDNF), amyloid-β (Aβ) clearance, and α-synuclein degradation, thereby linking metabolic and neurodegenerative pathways. Although the findings of Mu et al. derive from preclinical models, they provide a conceptual model for therapeutic strategies aimed at reproducing selected benefits of exercise in obesity, metabolic and neurodegenerative disorders. Notably, these effects appear to depend on sustained irisin exposure in preclinical systems, supporting a role for irisin as a regulator of long-term immunometabolic homeostasis. Collectively, these observations position the irisin/IL-33/Treg axis as a promising link between exercise, adipose tissue immunity, and systemic metabolic regulation, suggesting that targeting immunometabolic circuits, rather than energy balance alone, may open new avenues for future therapeutic intervention.

Confidence: 0.25 · 13 полей извлечено
Идентификация (6 полей)
Target
irisin
1.00
Alt. target
0.00
Protein family
0.00
Functional class
0.00
Subcellular loc.
0.00
Isoforms (metab/obesity)
0.00
Механизм действия (21 полей)
Mechanism
Irisin induces IL-33 production in adipose mesenchymal stromal cells, preserving ST2+ regulatory T cells in visceral adipose tissue, thereby restraining inflammation, improving insulin sensitivity, and promoting metabolic homeostasis.
0.95
Mutations (obesity/lean)
0.00
Activity (obesity)
0.00
Activity temporal
0.00
Energy balance
Irisin promotes metabolic homeostasis and systemic metabolic regulation, but the context emphasizes immunometabolic circuits rather than energy balance alone.
0.80
Appetite
0.00
Fat metabolism
Irisin modulates adipose tissue immune niches and contributes to thermogenic activation in subcutaneous adipose tissue.
0.85
Lipolysis
0.00
Thermogenesis
Irisin-driven IL-33 signaling in subcutaneous adipose tissue contributes to thermogenic activation.
0.90
Muscle metabolism
0.00
Inflammation
Irisin restrains inflammation in visceral adipose tissue by preserving ST2+ regulatory T cells.
0.95
Glucose metabolism
Irisin improves insulin sensitivity and has reported roles in glucose homeostasis.
0.90
AA metabolism
0.00
Hormonal pathways
Irisin is a myokine that acts on adipose tissue and has pleiotropic effects including cardiovascular protection and neurobiology.
0.85
Cell death
0.00
Adipocyte fibrosis
0.00
Upstream (biochem)
0.00
Upstream (physiol)
Exercise induces irisin production.
0.90
Downstream (biochem)
IL-33, ST2+ regulatory T cells, BDNF, amyloid-β clearance, α-synuclein degradation.
0.90
Downstream (physiol)
Improved insulin sensitivity, metabolic homeostasis, thermogenic activation, neuroprotection.
0.90
PTMs
0.00
Экспрессия (8 полей)
Tissue expression
adipose tissue
0.90
In vitro
0.00
In vivo
0.00
In silico
0.00
Genetic association
0.00
Ex vivo
0.00
Animal model
preclinical models
0.80
Diet/model
0.00
Клиника (11 полей)
Drug
0.00
Indication
0.00
Patient subgroups
0.00
Safety concerns
0.00
Off-target
0.00
Trial stage
0.00
Pharma competitors
0.00
AE severity
0.00
MOA weight loss
0.00
Endpoints
0.00
Approved
0.00